ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF

The present invention provides aryl phosphorus oxide compounds with kinase inhibitory activity. The compounds are capable of effectively inhibiting activity of various types of EGFR drug-resistant mutants (such as EGFRdel19, EGFRdel19/T790M, EGFRdel19/C797S, EGFRT790M/L8S8R, EGFRL8S8R/C797S, EGFRdel...

Full description

Saved in:
Bibliographic Details
Main Authors WANG, Xuechao, DENG, Ta, ZHANG, Rui, HUANG, Pei, ZHAO, Hai, CHEN, Shuang, HE, Peng, DONG, Guangxin, LI, Haiyan
Format Patent
LanguageEnglish
French
German
Published 03.07.2024
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides aryl phosphorus oxide compounds with kinase inhibitory activity. The compounds are capable of effectively inhibiting activity of various types of EGFR drug-resistant mutants (such as EGFRdel19, EGFRdel19/T790M, EGFRdel19/C797S, EGFRT790M/L8S8R, EGFRL8S8R/C797S, EGFRdel19/T790M/C797S, and EGFRL858R/T790M/C797S, and also have significant inhibitory effect on ALK fusion genes and mutants (such as L1 196M), and are capable of being used for the treatment, combined treatment or prevention of various types of cancers.
Bibliography:Application Number: EP20210831694